Price Chart

Profile

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
URL https://www.lyell.com
Investor Relations URL N/A
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Nov. 07, 2024 (est.)
Last Earnings Release Aug. 07, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
URL https://www.lyell.com
Investor Relations URL N/A
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Nov. 07, 2024 (est.)
Last Earnings Release Aug. 07, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A